Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kai Neben

Showing results (11-20 of 73) with videos related to

Pageof 8
Sort By:
Leukemia & Lymphoma|September 23, 2010
Quality of life of long-term survivors with Hodgkin lymphoma after high-dose chemotherapy, autologous stem cell transplantation, and conventional chemotherapyJuliane Brandt, Sascha Dietrich, Julia Meissner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2002
Dose-dependent effect of thalidomide on overall survival in relapsed multiple myelomaKai Neben, Thomas Moehler, Axel Benner, et al.
Annals of Hematology|November 20, 2003
Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomideMathias Witzens, Thomas Moehler, Kai Neben, et al.
Lancet (London, England)|November 27, 2007
Where is the primary tumour?Christian M Zechmann, Frederik L Giesel, Jens Hillengass, et al.
The American Journal of Pathology|October 28, 2003
Gene expression patterns in ependymomas correlate with tumor location, grade, and patient ageAndrey Korshunov, Kai Neben, Gunnar Wrobel, et al.
The Annals of Thoracic Surgery|December 4, 2013
Extended resection of a plasmocytoma of bone and an amyloidoma of the chest wallSeyer Safi, Jan Op den Winkel, Philipp A Schnabel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2011
Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routineTobias Meissner, Anja Seckinger, Thierry Rème, et al.
Blood|August 30, 2002
Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myelomaKai Neben, Joannis Mytilineos, Thomas M Moehler, et al.
Srpski Arhiv Za Celokupno Lekarstvo|February 23, 2012
The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratificationDirk Hose, Anja Seckinger, Anna Jauch, et al.
Radiology|September 21, 2010
Staging monoclonal plasma cell disease: comparison of the Durie-Salmon and the Durie-Salmon PLUS staging systemsKerstin Fechtner, Jens Hillengass, Stefan Delorme, et al.
Pageof 8

Showing results (11-20 of 73) with videos related to

Sort By:
Pageof 8
Leukemia & Lymphoma|September 23, 2010
Quality of life of long-term survivors with Hodgkin lymphoma after high-dose chemotherapy, autologous stem cell transplantation, and conventional chemotherapyJuliane Brandt, Sascha Dietrich, Julia Meissner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2002
Dose-dependent effect of thalidomide on overall survival in relapsed multiple myelomaKai Neben, Thomas Moehler, Axel Benner, et al.
Annals of Hematology|November 20, 2003
Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomideMathias Witzens, Thomas Moehler, Kai Neben, et al.
Lancet (London, England)|November 27, 2007
Where is the primary tumour?Christian M Zechmann, Frederik L Giesel, Jens Hillengass, et al.
The American Journal of Pathology|October 28, 2003
Gene expression patterns in ependymomas correlate with tumor location, grade, and patient ageAndrey Korshunov, Kai Neben, Gunnar Wrobel, et al.
The Annals of Thoracic Surgery|December 4, 2013
Extended resection of a plasmocytoma of bone and an amyloidoma of the chest wallSeyer Safi, Jan Op den Winkel, Philipp A Schnabel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2011
Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routineTobias Meissner, Anja Seckinger, Thierry Rème, et al.
Blood|August 30, 2002
Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myelomaKai Neben, Joannis Mytilineos, Thomas M Moehler, et al.
Srpski Arhiv Za Celokupno Lekarstvo|February 23, 2012
The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratificationDirk Hose, Anja Seckinger, Anna Jauch, et al.
Radiology|September 21, 2010
Staging monoclonal plasma cell disease: comparison of the Durie-Salmon and the Durie-Salmon PLUS staging systemsKerstin Fechtner, Jens Hillengass, Stefan Delorme, et al.
Pageof 8